1. Effect of Irbesartan on AGEs-RAGE and MMPs systems in rat type 2 diabetes myocardial-fibrosis model.
- Author
-
Hongwei Y, Ruiping C, Yingyan F, Guanjun Z, Jie H, Xingyu L, Jie T, Zhenghong L, Qin G, Junfeng H, and Heng Z
- Subjects
- Animals, Blood Glucose analysis, Body Weight, Collagen metabolism, Diabetes Mellitus, Type 2 etiology, Diabetic Cardiomyopathies etiology, Diet, High-Fat adverse effects, Fibrosis, Heart drug effects, Insulin blood, Irbesartan pharmacology, Male, Myocardium metabolism, Myocardium pathology, Rats, Rats, Sprague-Dawley, Tissue Inhibitor of Metalloproteinase-2 metabolism, Diabetes Mellitus, Type 2 complications, Diabetic Cardiomyopathies drug therapy, Glycation End Products, Advanced metabolism, Irbesartan therapeutic use, Matrix Metalloproteinases metabolism
- Abstract
Impact Statement: There are about 425 million diabetes patients (20-79 years) in the world according to the International Diabetes Federation Diabetes Atlas - 8th Edition. The cardiovascular complication is one of the major causes of death in diabetes patients. Myocardial fibrosis is one of the serious pathological changes, so investigating the pathogenesis of myocardial fibrosis has the significant value. Our study aims to investigate the effect of Irbesartan (the angiotensin II receptor antagonist) on the changes of AGE-RAGE system and MMP family components, and analyzes the potential mechanisms in type 2 diabetes-induced myocardial fibrosis. Our results provide the theoretical base for better understanding the pathogenesis in type 2 diabetes-induced myocardial complication. It is useful for clinicians to select the effective therapeutic measures for treatment of type 2 diabetes-induced organ fibrosis.
- Published
- 2019
- Full Text
- View/download PDF